Content Type: Article

  • Update on NAIC’s Consideration of AI Model Law for Insurers

    Update on NAIC’s Consideration of AI Model Law for Insurers

    ARTICLE / CLIENT ALERT

    Update on NAIC’s Consideration of AI Model Law for Insurers

    May 22, 2025

    Read time: 3 min

    Key takeaways
    Overview

    On May 12, 2025, the National Association of Insurance Commissioners’ (NAIC) Big Data and Artificial Intelligence (H) Working Group released a Request for Information (RFI), signaling that it may draft a model law to regulate insurers’ use of artificial intelligence (AI) systems.

    Building on the NAIC’s 2020 Principles on Artificial Intelligence and 2023 Model Bulletin on the Use of Artificial Intelligence Systems by Insurers, the RFI asks stakeholders whether uniform statutory requirements are needed across the United States and, if so, how they should address governance, transparency, and accountability. The questions explore whether obligations should vary by company size, how third-party vendors should be covered, whether existing state laws or industry templates might serve as models, and other related subjects. Written comments are due by June 30, 2025.

    Insurers, AI vendors, and other stakeholders should promptly assess whether they wish to provide comments and generally consider how a potential model law could affect their operations. Providing feedback during the RFI window could shape a future framework. The RFI is also a reminder to regulated entities of existing guidance on AI systems and the use of “Big Data” published by the NAIC and the New York State Department of Financial Services, as well as the novel Colorado legislation mandating certain anti-discrimination testing, among other requirements. Insurers and other stakeholders still have an early opportunity to proactively align internal legal and regulatory compliance strategies with potential future requirements, particularly around documenting AI use, mitigating discriminatory outcomes, and preparing for confidential examination tools that regulators are developing.

    In depth
    Authors

    Amber Adair

    Partner

    Dallas

    H. Michael Byrne

    Partner

    New York – One Vanderbilt Avenue

    Zachary (Zach) Couger

    Associate

    Chicago

    More insights

  • It is compensation data gathering season –  be a part of it.

    It is compensation data gathering season – be a part of it.

    ARTICLE / CLIENT ALERT

    It is compensation data gathering season – be a part of it.

    May 22, 2025

    Read time: 3 min

    Key takeaways
    Overview

    Our affiliate Eisenhandler & Co. is in the process of gathering the latest compensation data for the Alternative Investment Manager Industry utilizing their MarketLook Compensation Survey platform. Shelley Eisenhandler is the leading industry authority on compensation.

    MarketLook Compensation Survey

    From now through June 30, Eisenhandler & Co.’s MarketLook Compensation Survey is collecting compensation data from hedge fund, private equity, alternative credit, real estate and venture capital firms. The compensation survey highlights include:

    • Broad Market Reach: 200+ participating alternative investment managers
    • Role Scope Examples (including but not limited to):
      • Business Operations: Finance, HR, Legal & Compliance, Admin
      • Sales & Product: Capital Raising, Investor Relations, Client Service
      • Investments: Analysts, PMs, Deal Professionals, Operating Partners
      • Technology & Innovation: Engineering, Data, AI, Cybersecurity
    • Easy Access: Real-time dashboard with Excel export
    • Exclusive Benefits: Strategic compensation advice, insightful trends, year-end planning support and headcount analytics
    • Global coverage across Asia, Europe and the United States

    Interested in Participating?

    Whether you are benchmarking roles or preparing for year-end decisions, MarketLook delivers actionable insights. Results will be published in July. Please contact Shelley Eisenhandler, President – Eisenhandler & Co., to participate: shelley@eisenhandler.com or +1 203-903-7470.


    The Schulte & Eisenhandler Affiliation – Data Privacy

    Eisenhandler and Schulte operate separately and retain clients independently. Confidential client information held by Schulte and Eisenhandler is not shared with the other without the client’s written consent. When desired by a client, Schulte and Eisenhandler provide a coordinated “design-through-execution” approach to compensation plans, employment law advice, employee total reward and enterprise growth plans, firm ownership, and succession plans. Clients are free to engage Eisenhandler and/or Schulte, as they desire.

    We hope that you will participate in this year’s MarketLook survey.

    In depth
    Authors

    David Nissenbaum

    Partner

    New York – 919 Third Avenue

    Shelley Eisenhandler

    President of Eisenhandler & Co.

    New York – 919 Third Avenue

    Ian L. Levin

    Partner

    New York – 919 Third Avenue

    Martin L. Schmelkin

    Partner

    New York – 919 Third Avenue

    More insights

  • Washington’s Digital Ad Tax Enacted: Is Litigation Now Inevitable?

    Washington’s Digital Ad Tax Enacted: Is Litigation Now Inevitable?

    ARTICLE

    Washington’s Digital Ad Tax Enacted: Is Litigation Now Inevitable?

    May 21, 2025

    Read time: 4 min

    Key takeaways
    Overview

    On May 20, 2025, Washington Governor Bob Ferguson signed into law Senate Bill (SB) 5814, a sweeping tax bill that expands Washington’s retail sales and use tax to digital advertising services and a range of high-tech and IT services. The new law takes effect for sales occurring on and after October 1, 2025.

    As we noted previously, this legislation marks a significant shift in Washington’s tax policy, extending sales tax to categories of traditionally exempt business-to-business services. With enactment, legal challenges – particularly under the federal Internet Tax Freedom Act (ITFA) – are ripe and appear inevitable.

    WHAT THE LAW DOES

    SB 5814 amends RCW 82.04.050 by redefining “sale at retail” to include “advertising services,” broadly covering both digital and nondigital forms of ad creation, planning, and execution. The law specifically includes:

    • Online referrals
    • Search engine marketing
    • Lead generation optimization
    • Web campaign planning
    • Digital ad placement
    • Website traffic analysis

    However, the law expressly excludes services rendered in connection with:

    • Newspapers (RCW 82.04.214)
    • Printing or publishing (RCW 82.04.280)
    • Radio and television broadcasting
    • Out-of-home advertising (g., billboards, transit signage, event displays)

    With these carve-outs, it is difficult to see how anything other than internet advertising remains subject to tax. The structure of the new tax facially discriminates against e-commerce and is barred by ITFA.

    ITFA AND THE CERTAINTY OF A LEGAL CHALLENGE

    ITFA prohibits states from imposing taxes that discriminate against digital services when comparable offline equivalents are exempt. While SB 5814 purports to cover both digital and nondigital advertising, the exclusions for nondigital forms of advertising cause it to target the digital side of the industry. For example, a digital banner ad will be taxed, whereas a banner towed by an airplane promoting the same product will not.

    This distinction mirrors the structure of Maryland’s Digital Advertising Gross Revenues Tax, which has been tied up in litigation since its enactment in 2021. A Maryland trial court found that law facially violated ITFA and federal preemption principles. That litigation continues, and Washington now finds itself on a similar path.

    HIGH-TECH AND IT SERVICES ARE NOW TAXABLE

    In addition to digital advertising, SB 5814 extends the retail sales tax to high-tech services, including:

    • Custom website development
    • IT technical support and network operations
    • Data processing and data entry
    • In-person or live-virtual technical training

    Like advertising, these intermediate services typically are purchased by businesses in support of operations rather than for end consumption. Taxing their sale introduces tax pyramiding and adds costs that will ultimately be passed on to consumers. For Washington’s tech-driven economy, this change will inflate prices and reduce competitiveness.

    Local advertisers and businesses that rely on digital marketing and high-tech services will see these costs rise and lead to higher prices for consumers.

    OUTLOOK

    While SB 5814 is now law, its enforceability remains far from certain. Taxing digital advertising services while expressly excluding offline media places the new law on a collision course with ITFA. A legal challenge is all but guaranteed.

    At the same time, the law’s fiscal impact is speculative. Revenue projections assume compliance across a complex landscape of service transactions, but practical realities, including sourcing ambiguities, administrative burdens, and behavioral changes, may undermine the base.

    Washington, like Maryland, will find that taxing digital advertising is easier to legislate than to defend. The real test will come not in Olympia, but in the courts.

    For those interested in a deeper discussion of potential legal challenges or compliance considerations under the new law, please reach out to the authors.

    Authors

    Stephen P. Kranz

    Partner

    Washington, DC

    Mark Nebergall

    Counsel

    Washington, DC

    Jonathan C. Hague

    Associate

    Austin

    More insights
    Endnotes

  • Enforcement of Mental Health Parity Regulations Suspended: Takeaways for Plan Sponsors and Health Insurance Issuers

    Enforcement of Mental Health Parity Regulations Suspended: Takeaways for Plan Sponsors and Health Insurance Issuers

    CLIENT ALERT / US POLICY

    Enforcement of Mental Health Parity Regulations Suspended: Takeaways for Plan Sponsors and Health Insurance Issuers

    May 21, 2025

    Read time: 5 min

    Key takeaways
    Overview

    In January 2025, The ERISA Industry Committee (ERIC) filed a complaint against the US Departments of Labor, Health and Human Services, and the Treasury (the departments) seeking to invalidate the 2024 final regulations under the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) and the Consolidated Appropriations Act, 2021 (CAA). The US Department of Justice recently filed a motion for abeyance in the pending litigation, requesting that the court pause its review of the case and announcing that the Trump administration will stay enforcement of the final regulations to give the government an opportunity to reconsider the rule, “including whether to issue a notice of proposed rulemaking, rescinding or modifying the regulation.” The motion was approved on May 9, 2025.

    In depth

    On May 15, 2025, the departments issued a communication titled “Statement of U.S. Departments of Labor, Health and Human Services, and the Treasury Regarding Enforcement of the Final Rule on Requirements Related to the Mental Health Parity and Addiction Equity Act.” The departments’ action is at least partially in response to Executive Order 14219, titled “Ensuring Lawful Governance and Implementing the President’s ‘Department of Government Efficiency’ Deregulatory Initiative,” which directs federal agencies to review regulations to identify those that may impose undue burdens on small businesses or significant costs upon private parties that are not outweighed by public benefits.

    The statement is significant, as it advises that the departments “will not enforce the 2024 Final Rule or otherwise pursue enforcement actions, based on a failure to comply that occurs prior to a final decision in the litigation, plus an additional 18 months.” Notably, the relief applies only to those portions of the 2024 Final Rule that are newly added since the 2013 Final Rule. The statement reinstates the 2013 Final Rule, as interpreted by “FAQs About Mental Health and Substance Use Disorder Parity Implementation and the Consolidated Appropriations Act, 2021 Part 45.” The departments also note that MHPAEA’s statutory obligations, as amended by the CAA, continue to apply. In the case of the application of the MHPAEA rules within the jurisdiction of the department of Health and Human Services (i.e., the rules that apply to carriers), the statement encourages states, which are the primary enforcers of MHPAEA, to adopt a similar approach to enforcement.

    The statement restores the status quo that was in effect before the adoption of the 2024 Final Rule, with at least three immediate consequences:

    • The 2024 Final Rule’s “relevant data” requirement is suspended. Thus, compliance with the mental health parity requirements will no longer be tested on outcomes. Rather, the standard that applies temporarily is in the preamble to the 2013 final regulation (i.e., outcomes are not determinative of compliance).
    • The 2024 Final Rule’s controversial “meaningful benefit” requirement is also suspended. This is the requirement that a plan that provides any benefits for a mental health condition or substance use disorder in any classification of benefits must provide meaningful benefits for that mental health condition or substance use disorder in every classification in which medical/surgical benefits are provided. For this purpose, a plan does not provide meaningful benefits unless it also provides benefits for a core treatment for the mental health condition or substance use disorder in each such classification.
    • The 2024 Final Rule’s “fiduciary certification” requirement is suspended, at least temporarily. Absent the suspension, the 2024 Final Rule required fiduciaries to certify that they commissioned and reviewed an analysis of their compliance with the MHPAEA nonquantitative treatment limitations (NQTLs) requirements and that they selected and monitored their NQTL vendor.

    One important obligation that remains is the requirement to prepare and make available an NQTL comparative analysis. The continued application of the CAA also means that plan sponsors and health insurance issuers must continue with their compliance efforts.

    With respect to ongoing plan audits and investigations, the departments offered little insight as to how they may approach review or if their enforcement efforts may change moving forward. The statement notes that “The Departments will also undertake a broader reexamination of each department’s respective enforcement approach under MHPAEA” and that “the Departments may make updates to the subregulatory guidance implementing MHPAEA, including FAQs Part 45,” suggesting that some relief may be forthcoming. Additional guidance on the impact of the departments’ statement on these ongoing audit and enforcement activities would be welcome.

    Action Items

    Plan sponsors and health insurance issuers should continue to make good-faith efforts to comply with the MHPAEA guidance, as modified by the CAA. This includes, for example, preparation and maintenance of a written NQTL comparative analysis and ongoing review of benefit plans for compliance as applied to the plans’ written terms and operation.

    For more information on these changes, please contact your regular McDermott lawyer or one of the authors listed below.

    Authors

    Jacob M. Mattinson

    Partner

    Chicago

    Sarah G. Raaii

    Partner

    Chicago

    More insights

  • New UK Companies House Identity Verification Requirements

    New UK Companies House Identity Verification Requirements

    ARTICLE / CLIENT ALERT

    New UK Companies House Identity Verification Requirements

    May 21, 2025

    Read time: 5 min

    Key takeaways
    Overview

    Identity verification to become mandatory for directors of UK companies,  members of UK LLPs and PSCs of UK companies and LLPs from autumn.

    The Economic Crime and Corporate Transparency Act 2023 (“ECCTA”) introduced significant changes to Companies House procedure, with a view to improving transparency in particular over UK companies and LLPs and for the purpose of meeting four new statutory objectives: (i) to ensure that any person who is required to deliver a document to the Registrar of Companies does so (and that the requirements for proper delivery are complied with), (ii) to ensure that information contained in the public register is accurate and that the public register contains everything it ought to contain, (iii) to ensure that records kept by the Registrar of Companies do not create a false or misleading impression to members of the public and (iv) to prevent companies and others from carrying out unlawful activities or facilitating the carrying out by others of unlawful activities. These changes are being implemented over several years.

    As part of the above, ECCTA introduced procedures to verify the identity of company directors, LLP members, persons with significant control (“PSCs”) and any individual filing information on behalf of a company or LLP (such as a company secretary). Companies House has provided an update on how the identity verification (“IDV”) requirements imposed by the ECCTA will be implemented; it is now possible to voluntarily complete IDV with Companies House, and IDV is expected to become mandatory for new appointments and incorporations from autumn 2025. A 12-month transition period will start for companies that are already on the register on the date IDV becomes mandatory, during which period it will be necessary to complete IDV in connection with the submission of the entity’s annual confirmation statement.

    How to Verify Your Identity

    There are three methods to complete IDV for those required (each, an “Applicant”) to do so:

    1. online, either through the Gov.UK One Login app or web service;
    2. face-to-face at a UK post office ; or
    3. via an authorised corporate service provider (“ACSP”)

    The process and the types of accepted identification documentation differ according to the method used, though the Gov.UK One Login app route is likely to be simpler for those Applicants who hold a biometric passport (which need not be UK issued). Verification via the app, the web service or face-to-face is free of charge; however, ACSPs may charge a fee for using their IDV service. Unless IDV is completed through an ACSP, Applicants will be required to create an account with the Gov.UK One Login service, and with the Companies House Service, in order to complete the IDV procedure. Each applicant must complete the IDV procedure themselves and provide a unique email address that has not previously been used for this purpose.

    Other Considerations

    Once an Applicant has successfully completed IDV, a personal code will be issued to the Applicant. This code will be required to link each individual’s verified identity to Companies House records to ensure that the correct identity is linked to all roles held by that individual. The code will also be required in connection with filing confirmation statements and appointments of directors, LLP members and PSCs.

    Whilst we will of course provide advice and guidance regarding the IDV process to clients that have existing UK entities or who wish to form a new one, we will not be able to complete the IDV process on behalf of our clients. It is important to ensure that IDV is completed in good time for each individual appointed as a director, LLP member or PSC, and for any individual filing information on behalf of the relevant entity, and to note that following the IDV procedures becoming mandatory later this year, incorporation times for new UK vehicles will likely increase where IDV has not been completed in advance.

    Authored by Jim McNally and Adam Frost.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel International LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel International LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors
    More insights

  • “Big, Beautiful Bill”: Federal Tax Bill Would Restrict the Employee Retention Credit

    “Big, Beautiful Bill”: Federal Tax Bill Would Restrict the Employee Retention Credit

    ARTICLE

    “Big, Beautiful Bill”: Federal Tax Bill Would Restrict the Employee Retention Credit

    May 20, 2025

    Read time: 3 min

    A sweeping federal tax bill that is currently under consideration in the US House of Representatives contains provisions that would significantly change the administration and enforcement of the Employee Retention Credit (ERC).

    The ERC was enacted in 2020 as part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act to provide financial relief to businesses affected by the COVID-19 pandemic by incentivizing employers to retain employees on payroll and rehire displaced workers. The ERC allowed employers that experienced significant disruptions due to government orders or a substantial decline in gross receipts to claim a tax credit equal to a percentage of qualified wages paid to employees. Millions of employers have filed refund claims seeking ERC for periods in 2020 and 2021. Since the enactment of the CARES Act, the Internal Revenue Service (IRS) has issued roughly $250 billion in ERC. More than 500,000 claims remained pending as of April 2025.

    The federal tax bill, dubbed the “Big, Beautiful Bill” by US President Donald Trump, would prevent the IRS from allowing ERC that was claimed by a taxpayer on or before January 31, 2024. The deadline to claim ERC for taxable quarters in 2020 was April 15, 2024, and the deadline to claim ERC for taxable quarters in 2021 was April 15, 2025. The tax bill would thus appear to render ineligible all pending claims that were made after January 31, 2024, which are likely to be considerable in number. The bill is ambiguous as to whether taxpayers who have already been allowed ERC would need to repay those amounts to the extent their claims were made after January 31, 2024.

    The tax bill would also extend the statute of limitations on the IRS’s ability to assess amounts attributable to ERC. Presently, the IRS has three years to assess amounts associated with ERC for all periods in 2020 and for Q1 and Q2 of 2021. The IRS has five years to assess amounts associated with ERC for Q3 and Q4 of 2021. The proposed legislation would extend both of these limitations periods to six years. This change would be significant, especially because the IRS is authorized to assess and collect erroneously allowed ERC by notice and demand.

    Practice Point:

    Taxpayers with pending ERC claims should be alert to ongoing legislative developments – as this area continues to be a prominent focus of federal tax policy – and prepare now to defend ERC claims (even those filed after the potentially new deadline of January 31, 2024). Enactment of the changes proposed in the tax bill could dramatically restrict the amount of ERC currently eligible to be paid or credited and may empower the IRS to recapture a greater amount of claims already allowed. But considerable uncertainties remain as to the scope of the changes proposed in the bill. In the face of this uncertainty, taxpayers should consult experienced counsel who can assist them in preparing to defend ERC claims to which they are entitled.

    In depth
    Authors

    Shawn O'Brien

    Partner

    Houston

    Michael J. Scarduzio

    Partner

    New York – One Vanderbilt Avenue

    Samuel F. Hamer

    Associate

    Washington, DC

    More insights
    Endnotes

  • EU Savings and Investment Union: Whatever it takes?

    EU Savings and Investment Union: Whatever it takes?

    ARTICLE

    EU Savings and Investment Union: Whatever it takes?

    May 16, 2025

    Read time: 2 min

    Key takeaways
    Overview

    On March 19, 2025, the European Commission presented its ambitious strategy for a Savings and Investment Union (SIU), with the aim of giving EU citizens better access to capital markets and opening up new financing channels for companies. Insurers and pension funds in particular are set to benefit from expanded opportunities in the areas of risk capital, private equity, and infrastructure. At the same time, the strategy will bring about profound changes and new challenges for companies and institutions in the EU, which will need to be understood and addressed.

    In their article “EU Savings and Investment Union: Whatever it takes?”, published in Versicherungsmonitor, Renate Prinz and Dr. Cornelius Hille provide an in-depth analysis of the planned changes and explain the specific implications of the new strategy for companies, the financial sector, and EU supervision. They offer valuable insights into the practical challenges and opportunities arising from the implementation of the strategy.

    In depth
    Authors

    Dr. Cornelius Hille

    Associate

    Frankfurt

    More insights

  • IRS Roundup May 2 – May 13, 2025

    IRS Roundup May 2 – May 13, 2025

    ARTICLE

    IRS Roundup May 2 – May 13, 2025

    May 19, 2025

    Read time: 5 min

    Check out our summary of significant Internal Revenue Service (IRS) guidance and relevant tax matters for May 2, 2025 – May 13, 2025.

    IRS GUIDANCE

    May 2, 2025: The IRS issued Revenue Procedure 2025-20, providing guidance on the domestic asset/liability percentages and domestic investment yields used by foreign life insurance companies and foreign property and liability insurance companies to compute their minimum effectively connected net investment income under Section 842(b) of the Internal Revenue Code (Code) for taxable years beginning after December 31, 2023.

    May 5, 2025: The IRS released Internal Revenue Bulletin 2025-19, which includes Revenue Ruling 2025-10 and Revenue Procedure 2025-18.

    Revenue Ruling 2025-10 provides various prescribed rates for federal income tax purposes for May 2025, including:

    • The short-, mid-, and long-term applicable federal rates for purposes of Code Section 1274(d).
    • The short-, mid-, and long-term adjusted applicable federal rates for purposes of Code Section 1288(b).
    • The adjusted federal long-term rate and the long-term tax-exempt rate from Code Section 382(f).
    • The appropriate percentages for determining the low-income housing credit from Code Section 42(b)(1) (but only for buildings placed in service during May 2025).
    • The federal rate for determining the present value of an annuity, an interest for life or for a term of years, or a remainder or a reversionary interest for purposes of Code Section 752.

    Revenue Procedure 2025-18 provides issuers of qualified mortgage bonds (defined in Code Section 143(a)) and mortgage credit certificates (defined in Code Section 25(c)) with guidance related to nationwide purchase prices for residences, as well as the average area purchase price for residences located in statistical areas in each US state, the District of Columbia, Puerto Rico, the Northern Mariana Islands, American Samoa, the Virgin Islands, and Guam.

    May 6, 2025: The IRS issued Revenue Procedure 2025-21, modifying Section 12 of Revenue Procedure 2024-32.

    Executive Order 14219, issued through the Department of Government Efficiency’s deregulatory initiative, directed agencies to initiate a review process for identification and removal of certain regulations and guidance. Pursuant to Executive Order 14219, the US Department of the Treasury and the IRS identified Section 12 of Revenue Procedure 2024-32 as a regulation needing modification.

    Revenue Procedure 2024-32 specifies the procedure by which the sponsor of a defined benefit plan, which is subject to the funding requirements of Code Section 430, may request approval from the IRS for the use of plan-specific substitute mortality tables. Section 12.02 of Revenue Procedure 2024-32 specifies that if a plan sponsor wishes to use plan-specific mortality tables, it must develop and request approval for the use of new plan-specific mortality tables for plan years beginning on or after January 1, 2026. Revenue Procedure 2025-21 provides immediate relief for some of those plan sponsors by narrowing the category of plan sponsors that must request approval of new plan-specific substitute mortality tables.

    May 12, 2025: The IRS issued Revenue Ruling 2025-11, determining the interest rates on overpayments and underpayments of tax under Code Section 6621. For corporations, an overpayment rate of 6% and an underpayment rate of 7% is established for the calendar quarter beginning July 1, 2025. Where a portion of a corporate overpayment exceeds $10,000 during the calendar quarter beginning July 1, 2025, the overpayment rate is 4.5%. For large corporate underpayments, the underpayment rate for the calendar quarter beginning July 1, 2025, is 9%.

    May 12, 2025: The IRS released Internal Revenue Bulletin 2025-20, which includes Notice 2025-25 and Notice 2025-26.

    Notice 2025-25 publishes the inflation adjustment factor for credits under Code Section 45Q on carbon oxide sequestration, which is used to determine the amount of the credit allowable under Section 45Q for taxpayers that make an election under Code Section 45Q(b)(3) to have the dollar amounts applicable under Code Section 45Q(a)(1) or (2) apply.

    Notice 2025-26 publishes the reference price under Code Section 45K(d)(2)(C) for calendar year 2024. The reference price applies in determining the amount of the enhanced oil recovery credit under Code Section 43, the marginal well production credit for qualified crude oil production under Code Section 45I, and the applicable percentage under Code Section 613A used in determining the percentage of depletion in the case of oil and natural gas produced from marginal properties.

    The IRS also released its weekly list of written determinations (e.g., Private Letter Rulings, Technical Advice Memorandums, and Chief Counsel Advice).

    THE “BIG, BEAUTIFUL BILL”

    A recent tax bill, which some practitioners are calling the “Big, Beautiful Bill,” is currently being deliberated in Congress. As of the publication date of this edition of the IRS Roundup, a few of the notable provisions in the Big, Beautiful Bill include:

    • A proposed disallowance of “substitute payments” related to state and local taxes.
    • The proposal of a 23% pass-through business deduction, up from the current deduction of 20%.
    • The renewal of a research and development expensing provision through 2029, including a 100% bonus depreciation.
    • A phaseout of certain clean electricity credits, marking a notable change to the Inflation Reduction Act of 2022.
    • The reinstatement of a partial charitable contribution deduction for nonitemizers.
    • The proposed disallowance of certain amortization deductions for sports franchises.
    • An extension of various provisions expected to sunset in 2026.
    In depth
    Authors

    Evan Walters

    Partner

    Chicago

    Samuel F. Hamer

    Associate

    Washington, DC

    Edward L. Froelich

    Counsel

    Washington, DC

    Michael J. Scarduzio

    Partner

    New York – One Vanderbilt Avenue

    More insights
    Endnotes

  • Investment Opportunities in TechBio and Pharma Services

    Investment Opportunities in TechBio and Pharma Services

    ARTICLE

    Investment Opportunities in TechBio and Pharma Services

    May 2025

    Read time: 5 min

    Overview

    In April 2025, McDermott once again hosted its annual European Health & Life Sciences Symposium at the Shangri-La hotel in Paris. Attended by some 300 delegates from across the industry, participants including investors, innovators, finance providers and advisers enjoyed a wide-ranging agenda covering everything from transaction trends and financing innovation through to navigating policy shifts and identifying investment opportunities.

    In an era of intense innovation at the intersection of technology and biology, the healthcare industry is witnessing unprecedented advancements that present exciting openings for investors. “The dynamic world of companies applying innovative technology platforms to reshape drug discovery and patient care is presenting a new wave of investment opportunities,” says Anne-France Moreau, partner at McDermott.

    In depth

    Latest Innovation Trends

    Two key segments of the health and life sciences ecosystem were identified as optimising growth and development and creating investment opportunities. First, the symposium heard about the TechBio space, where digital technology platforms and solutions support drug discovery and drug development. Second, the opportunities related to solutions and technologies that support healthcare and pharma services were discussed.

    The primary goal of TechBio solutions is to derisk the process of identifying potential drugs and assets by improving the chances of success. The buzz around the application of AI and computer science in biology has attracted new types of investors into TechBio and pharma services, with tech-focused capital coming from venture capital into the biotech space. We have seen a surge in company creation in technology-enabled healthcare, but it covers such a wide range of innovations and business models, it can be complex for investors to navigate.

    Assessing Opportunities

    Considering the key metrics for assessing opportunities in TechBio, investors spoke about the need to look not only at the assets being developed but also the data that has been generated, though the specifics will vary by business model.

    While there is a temptation for TechBio companies to be both services and biotech businesses, that is difficult for investors who tend to come from one side or another. Those that actively invest in services are less likely to be willing to take on binary regulatory or clinical risk exposures, for example.

    In pharma services, investors are looking at indicators that include the client base, recurring revenues, scalability, management team and the pathway to profitability. Often, they will focus in on the financial metric that will be used for valuation by an acquirer, which may be earnings but might also be annual recurring revenues. And investors look for partners with realistic valuation expectations.

    Investors in these types of companies often look for business moats that are idiosyncratic, whether those are technology, IP, clinical data or regulatory approvals that will give a competitive advantage.

    Access to data can be a key policy issue for these businesses, which often rely on some combination of molecular, clinical and biological data. Discussions around sourcing reliable data, complying with relevant regulatory frameworks and protecting intellectual property will be important.

    Challenges for Investors

    While there is much excitement about the application of AI tools in drug development, the innovators present highlighted the fact that AI can only work with past data and the quality of the data set is critical, so genuine innovation is challenging. Likewise, areas like cell and gene therapy are new and complex areas so the technology and proof of concept is still to be developed, which can be challenging for investors.

    There is also a risk that AI and machine learning tools may become commoditised over time, so valuations should not necessarily be based on those technologies but rather on new molecules, clinical data, growth rates and management capabilities. Any use of AI needs to pay close attention to ethics, with clear accountability, responsibility and human decision-making.

    Where investors see a multiplication of risk around new technologies in drug development, biotech businesses often find it easier to turn to big pharma for funding because they are more able to get comfortable with that risk. However, some TechBio businesses have platforms that they wish to license to big pharma and seek partnerships, which can create challenges for exit models.

    Monika Richter, partner with McDermott, says: “There are many opportunities for investors to leverage innovations in TechBio and pharma services that have the potential to improve drug development processes and patient outcomes. These are exciting and complex emerging areas that are attracting new investors into the healthcare space, but the legal and regulatory frameworks are co-developing in real time, creating a dynamic environment that needs to be navigated with care.”

    More insights

  • Battery storage on the rise – Latest legal developments and current legislative changes

    Battery storage on the rise – Latest legal developments and current legislative changes

    ARTICLE

    Battery storage on the rise – Latest legal developments and current legislative changes

    19. Mai 2025

    Read time: 2 min

    Key takeaways
    Overview

    The high fluctuations in electricity prices, coupled with continuing declines in battery cell prices, are creating an attractive environment for battery energy storage systems (BESS) in Germany. In addition, a developing market for PPAs and tolling agreements is making investments in BESS projects increasingly attractive for infrastructure investors.

    The latest energy reform package from the traffic light coalition has also brought in a number of legislative changes that will further promote the growth of BESS, even if some important issues (including grid connection procedures and building permit requirements) still require further adjustment.

    Learn more about the latest developments and their impact on the future of energy storage in Germany in the full article by Dr. Maximilian Uibeleisen and Dr. Simon Groneberg, published in VDI energie + umwelt, Vol. 02 | 2025 | No. 5-6.

    In depth
    Authors
    More insights